Analysts May Have Underestimated Argenx SE’s (ARGX) 5 year Revenue Growth

Core Viewpoint - Argenx SE (NASDAQ:ARGX) is identified as one of the top growth stocks on NASDAQ for the next decade, with positive ratings and significant upside potential from analysts [1][2]. Analyst Ratings and Price Targets - H.C. Wainwright maintains a Buy rating on Argenx SE with a price target of $915, indicating an 8.93% upside from current levels [1]. - Wells Fargo has also reiterated a Buy rating, increasing its price target from $1,264 to $1,317, suggesting a potential upside of 55% from current levels [2]. Revenue Estimates - Wells Fargo has raised its revenue estimates for Argenx's product Vyvgart for the 2026-2030 period by 5%-15%, reflecting expectations of stronger performance [3]. - The consensus revenue estimate for FY 2026 is $5.6 billion, which Wells Fargo believes underestimates the company's growth potential, projecting revenues could reach $6.5 billion with single-digit quarter-over-quarter growth in Q1 and low double-digit growth from Q2 to Q4 [3]. Company Overview - Argenx SE is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases, operating in multiple countries including the Netherlands, the United States, China, and Japan [4]. - The company's product lineup includes VYGART HYTRULO and VYGART, and it was founded in 2008, headquartered in Amsterdam, the Netherlands [4].